Guillain-Barre Syndrome linked to SARS-CoV-2 infection – meta-analysis and literature review
DOI:
https://doi.org/10.12775/JEHS.2023.25.01.004Keywords
AIDP, AMSAN, COVID-19, GBS, SARS-CoV-2Abstract
Background
The novel coronavirus disease-2019 (COVID-19), which is caused by Severe Acute Respiratory Distress Syndrome coronavirus 2 (SARS-CoV2), was originally detected in Wuhan, China in December 2019. In this meta-analysis and literature review, we compared and summarized the clinical presentation, cerebrospinal fluid (CSF) and electromyography (EMG) findings and outcomes in SARS-CoV-2 patients with Guillain-Barre Syndrome (GBS) and its variants.
Methods
We conducted a literature review in February 2023 searching for terms “Guillain-Barre Syndrome and COVID-19", “SARS neurology”, “COVID-19 complications”. We used PubMed and Google Scholar databases inquiring case reports or series of cases published between April 1, 2020, and September 14, 2023.
Results
Of the 52 GBS cases 61,5% (n=32) were male and 39,5% (n=20) were female. The mean age was 57 years old. A total of 75% (n=33) patients presented acute inflammatory demyelinating polyneuropathy (AIDP) variant, 6,8% (n=3) presented acute motor axonal neuropathy (AMAN) variant, 15,9% (n=7) presented acute motor-sensory axonal neuropathy (AMSAN) variant. A total of 85,7% (n=42) of patients were diagnosed with albuminocytological dissociation. During the hospitalization, a total of 30,8% (n=16) required mechanical ventilation. A total of 61,5% (n=32) of patients were treated with a 5-day regimen of intravenous immunoglobulin (IVIG) in dose 0.4 g/kg/day. There were 46,1% (n=24) complete recoveries from GBS, 32,7% (n=17) partial recoveries and 9,6% (n=5) of patients did not respond to treatment. A total of 11,5% (n=6) of patients died.
Conclusion
It is crucial to follow patients with COVID-19 and GBS over time to estimate properly the efficacy of treatment and evaluate the real percentage of recovery and complications.
References
WHO coronavirus (COVID-19) dashboard. WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Accessed January 26, 2023. https://covid19.who.int/
Taubenberger JK, Morens DM. 1918 Influenza: the Mother of All Pandemics. Emerging Infectious Diseases. 2006;12(1). doi:10.3201/eid1201.050979
Peeri NC, Shrestha N, Rahman MS, et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? International Journal of Epidemiology. 2020;49(3):717-726. doi:10.1093/ije/dyaa033
Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity. 2020;87. doi:10.1016/j.bbi.2020.03.031
Li Y, Bai W, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. Journal of Medical Virology. 2020;92(6). doi:10.1002/jmv.25728
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chemical Neuroscience. 2020;11(7). doi:10.1021/acschemneuro.0c00122
Berger JR. COVID-19 and the nervous system. Journal of Neurovirology. 2020;26(2). doi:10.1007/s13365-020-00840-5
Teixeira-Vaz A, Rocha JA, Reis DA e, et al. Critical COVID-19 and neurological dysfunction - a direct comparative analysis between SARS-CoV-2 and other infectious pathogens. Revista Brasileira de Terapia Intensiva. 2022;34(3). doi:10.5935/0103-507X.20220229-en
Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. The Lancet Neurology. 2020;19(9). doi:10.1016/S1474-4422(20)30221-0
Chams N, Chams S, Badran R, et al. COVID-19: A Multidisciplinary Review. Frontiers in Public Health. 2020;8. doi:10.3389/fpubh.2020.00383
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2003;395(10229). doi:10.1016/S0140-6736(20)30566-3
Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurological Sciences. 2020;41(6). doi:10.1007/s10072-020-04449-8
Shang P, Feng J, Wu W, Zhang HL. Intensive Care and Treatment of Severe Guillain–Barré Syndrome. Frontiers in Pharmacology. 2021;12. doi:10.3389/fphar.2021.608130
Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. The Lancet. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
Agosti E, Giorgianni A, D’Amore F, Vinacci G, Balbi S, Locatelli D. Is Guillain-Barrè syndrome triggered by SARS-CoV-2? Case report and literature review. Neurological Sciences. 2021;42(2). doi:10.1007/s10072-020-04553-9
Noon A, Malhi JK, Wong CK. Atypical Guillain-Barré Syndrome Presenting After COVID-19 Infection. Cureus. 2022;14(9). doi:10.7759/cureus.29521
Ilyas U, Umar Z, Bhangal R, Shah D, Fayman B. Guillain-Barré Syndrome: A Sequela of the Original COVID-19 Infection or Vaccination. Cureus. 2022;14(8). doi:10.7759/cureus.28044
Ahmad T, Hamdan S, Saadeh I. Guillain–Barré Syndrome Associated with COVID-19: Two Cases from a Public Hospital in Damascus, Syria. Case Reports in Medicine. 2022;2022. doi:10.1155/2022/9722736
Miyajan KF, Alyamani NA, Zafer DO, Tawakul AA. Guillain-Barré Syndrome in an Elderly Patient as a Complication of COVID-19 Infection. Cureus. 2021;13(10). doi:10.7759/cureus.19154
Al-Zadjali MM, Shibli EA, Maskari MA, Gujjar AR, Asmi AA. Post-COVID-19 Guillain-Barré Syndrome: A case report from Oman. Sultan Qaboos University Medical Journal. 2022;22(3). doi:10.18295/squmj.6.2021.090
Khaja M, Gomez GPR, Santana Y, et al. A 44-Year-Old Hispanic Man with Loss of Taste and Bilateral Facial Weakness Diagnosed with Guillain-Barré Syndrome and Bell’s Palsy Associated with SARS-CoV-2 Infection Treated with Intravenous Immunoglobulin. The American Journal of Case Reports. 2020;21. doi:10.12659/AJCR.927956
Sharma S, Adhikari A, Ghimire N, Mainali G, Yadav SK, Rajkarnikar R. Guillain-Barré Syndrome associated with SARS-CoV-2 infection in Nepal: A case report. Annals of Medicine and Surgery. 2022;80. doi:10.1016/j.amsu.2022.104214
Ivan AP, Odajiu I, Popescu BO, Davidescu EI. COVID-19 Associated Guillain–Barré Syndrome: A Report of Nine New Cases and a Review of the Literature. Medicina. 2022;58(8). doi:10.3390/medicina58080977
Devarakonda AK, Stumpe TR, Saucier AN, Riley T. Neurological Consequences of COVID-19: A Curious Case of Delayed Onset Guillain-Barre. Cureus. 2022;14(5). doi:10.7759/cureus.25325
Cea G, Romero C, Aguilar S, et al. Guillain-Barré syndrome in patients with SARS-CoV-2 infection. Report of three cases. Revista médica de Chile. 149(12):1812-1816. doi:10.4067/s0034-98872021001201812
Rane RP, Jain A, Hussain KM, Naik S, Shahab A. A Rare Case of Guillain-Barré Syndrome Associated With SARS-CoV-2 Infection Requiring Mechanical Ventilation. Cureus. 2022;14(6). doi:10.7759/cureus.25810
Živković V, Gačić EM, Djukić D, Nikolić S. Guillain–Barré syndrome as a fatal complication of SARS-CoV-2 infection – An autopsy case. Legal Medicine (Tokyo, Japan). 2022;57. doi:10.1016/j.legalmed.2022.102074
Carpenter K, Iqbal A, Singh R, et al. COVID-19 Infection and Guillain-Barre Syndrome: A Case Series. Cureus. 2022;14(2). doi:10.7759/cureus.21998
Nigatu D, Tigabu T, Awraris M, Yohannes A, Kebede D. Guillain-Barré Syndrome Associated with SARS CoV-2 Infection: Case Report. Ethiopian Journal of Health Sciences. 2022;32(1). doi:10.4314/ejhs.v32i1.21
Kaeley N, Kabi A, Pillai A, Shankar T, S alva AMS. Post-COVID-19 Guillain-Barré Syndrome: A Case Report With Literature Review. Cureus. 2022;14(1). doi:10.7759/cureus.21246
Toy E, Kart K. Intensive care management in guillain barré syndrome accompanying prolonged Covid-19–A case report. Nigerian Journal of Clinical Practice. 2022;25(2). doi:10.4103/njcp.njcp_85_21
Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet Neurology. 2020;19(5). doi:10.1016/S1474-4422(20)30109-5
Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience. 2020;76. doi:10.1016/j.jocn.2020.04.062
Ottaviani D, Boso F, Tranquillini E, et al. Early Guillain-Barré syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital. Neurological Sciences. 2020;41(6). doi:10.1007/s10072-020-04449-8
Alberti P, Beretta S, Piatti M, et al. Guillain-Barré syndrome related to COVID-19 infection. Neurology® Neuroimmunology & Neuroinflammation. 2020;7(4). doi:10.1212/NXI.0000000000000741
Padroni M, Mastrangelo V, Asioli GM, et al. Guillain-Barré syndrome following COVID-19: new infection, old complication? Journal of Neurology. 2020;267(7). doi:10.1007/s00415-020-09849-6
Coen M, Jeanson G, Almeida LAC, et al. Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. Brain, Behavior, and Immunity. 2020;87. doi:10.1016/j.bbi.2020.04.074
Otmani HE, Moutawakil BE, Rafai MA, et al. Covid-19 and Guillain-Barré syndrome: More than a coincidence! Revue Neurologique. 2020;176(6). doi:10.1016/j.neurol.2020.04.007
Scheidl E, Canseco DD, Hadji‐Naumov A, Bereznai B. Guillain‐Barr é syndrome during SARS‐CoV ‐2 pandemic: A case report and review of recent literature. Journal of the Peripheral Nervous System. 2020;25(2):204-207. doi:10.1111/jns.12382
Riva N, Russo T, Falzone YM, et al. Post-infectious Guillain–Barré syndrome related to SARS-CoV-2 infection: a case report. Journal of Neurology. 2020;267(9). doi:10.1007/s00415-020-09907-z
Assini A, Benedetti L, Maio SD, Schirinzi E, Sette MD. New clinical manifestation of COVID-19 related Guillain-Barrè syndrome highly responsive to intravenous immunoglobulins: two Italian cases. Neurological Sciences. 2020;41(7). doi:10.1007/s10072-020-04484-5
Bigaut K, Mallaret M, Baloglu S, et al. Guillain-Barré syndrome related to SARS-CoV-2 infection. Neurology® Neuroimmunology & Neuroinflammation. 2020;7(5). doi:10.1212/NXI.0000000000000785
Chan JL, Ebadi H, Sarna JR. Guillain-Barré Syndrome with Facial Diplegia Related to SARS-CoV-2 Infection. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques. 2020;47(6):852-854. doi:10.1017/cjn.2020.106
Toscano G, Palmerini F, Ravaglia S, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. New England Journal of Medicine. 2020;382(26):2574-2576. doi:10.1056/nejmc2009191
Lascano AM, Epiney J ‐b., Coen M, et al. SARS‐CoV‐2 and Guillain–Barré syndrome: AIDP variant with a favourable outcome. European Journal of Neurology. 2020;27(9). doi:10.1111/ene.14368
Berg B van den, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis - PubMed. Nature reviews Neurology. 2014;10(8). doi:10.1038/nrneurol.2014.121
Caress JB, Castoro RJ, Simmons Z, et al. COVID‐19–associated Guillain‐Barré syndrome: The early pandemic experience. Muscle & Nerve. 2020;62(4). doi:10.1002/mus.27024
Jacobs BC, van Doorn PA, Tio-Gillen AP, et al. Campylobacter jejuni infections and anti‐GM1 antibodies in guillain‐barré syndrome. Annals of Neurology. 40(2):181-187. doi:10.1002/ana.410400209
Dimachkie MM, Barohn RJ. Guillain-Barré Syndrome and Variants. Neurologic clinics. 2013;31(2). doi:10.1016/j.ncl.2013.01.005
Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain‐Barré syndrome - Hughes, RAC - 2014. Cochrane Database of Systematic Reviews. 2014;(9). doi:10.1002/14651858.CD002063.pub6
Shang P, Feng J, Wu W, Zhang HL. Intensive Care and Treatment of Severe Guillain–Barré Syndrome. Frontiers in Pharmacology. 2021;12. doi:10.3389/fphar.2021.608130
Verboon C, van Doorn PA, Jacobs BC. Treatment dilemmas in Guillain-Barré syndrome. Journal of Neurology, Neurosurgery & Psychiatry. 2017;88(4):346-352. doi:10.1136/jnnp-2016-314862
Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain‐Barré syndrome. The Cochrane Database of Systematic Reviews. 2017;2017(2). doi:10.1002/14651858.CD001798.pub3
Beydoun HA, Beydoun MA, Hossain S, Zonderman AB, Eid SM. Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain‐Barré syndrome. Muscle & Nerve. 61(5):608-615. doi:10.1002/mus.26831
Greene-Chandos, Torbey. Critical Care of Neuromuscular Disorders : CONTINUUM: Lifelong Learning in Neurology. LWW. https://journals.lww.com/continuum/Abstract/2018/12000/Critical_Care_of_Neuromuscular_Disorders.11.aspx
Kleyweg RP, Meché FG van der. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. Journal of Neurology, Neurosurgery, and Psychiatry. 1991;54(11). doi:10.1136/jnnp.54.11.957
El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Critical Care. 2011;15(4). doi:10.1186/cc10305
Charra B, Hachimi A, Benslama A, Motaouakkil S. Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome. The Pan African Medical Journal. 2014;18. doi:10.11604/pamj.2014.18.35.2911
Islam B, Islam Z, Rahman S, et al. Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study. BMJ Open. 2018;8(8). doi:10.1136/bmjopen-2018-022862
Hahn AF. The Challenge of Respiratory Dysfunction in Guillain-Barré Syndrome. Archives of Neurology. 2001;58(6):871-872. doi:10.1001/archneur.58.6.871
Chakraborty, Kramer, Wijdicks, Rabinstein. Dysautonomia in Guillain–Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocritical Care. 2019;32(1):113-120. doi:10.1007/s12028-019-00781-w
Shang P, Zhu M, Baker M, Feng J, Zhou C, Zhang HL. Mechanical ventilation in Guillain-Barré syndrome - PubMed. Expert review of clinical immunology. 2020;16(11). doi:10.1080/1744666X.2021.1840355
Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF. Anticipating mechanical ventilation in Guillain-Barré syndrome - PubMed. Archives of neurology. 2001;58(6). doi:10.1001/archneur.58.6.893
Green C, Baker T, Subramaniam A. Predictors of respiratory failure in patients with Guillain-Barré syndrome: a systematic review and meta-analysis - PubMed. The Medical journal of Australia. 2018;208(4). doi:10.5694/mja17.00552
Umer SR, Nisa Q, Kumari M, Abbas S, Mahesar SA, Shahbaz NN. Clinical Features Indicating the Need for Mechanical Ventilation in Patients with Guillain Barre Syndrome. Cureus. 2019;11(8):e5520. doi:10.7759/cureus.5520
Hadden RDM, Cornblath DR, Hughes RAC, et al. Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome. Annals of Neurology. 44(5):780-788. doi:10.1002/ana.410440512
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Nikola Siekierko, Maja Żołnierek, Wiktoria Kotusiewicz, Mateusz Lewandowski, Grzegorz Bienia, Zuzanna Lubczyńska, Yevheniia Popravko, Jakub Świętochowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 488
Number of citations: 0